- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Virus Inactivation in the 1990s ? and into the 21st Century: Part 5: Disinfection
by Gail Sofer, BioReliance Both the process and the product strongly influence viral inactivation, and unknown or unspecified details ? such as variability in virus titers, measuring devices, calibrations, and protocols ? can all influence log reduction values. This article series covers what you need to know to fully understand the properties of the test article, the viruses inactivated, and the critical control parameters for selected inactivation methods.
Articles in this issue
over 22 years ago
Becoming a Partner of Choice and Evaluating Prospective Alliancesover 22 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counselorover 22 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechover 22 years ago
Survival Strategies: Keeping Tabs on Trainingover 22 years ago
Outsourcing Outlook: Contract Services' Crystal BallNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.